Scientists probe hidden cell chatter in diabetes

NCT ID NCT07224334

Recruiting now Knowledge-focused Sponsor: David D'Alessio, M.D. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase study looks at how alpha cells in the pancreas communicate with beta cells to control blood sugar. Researchers will give healthy volunteers exendin-9 (a GLP-1 blocker) and dexamethasone to see how insulin secretion changes. The goal is to better understand diabetes, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Exendin-9 and dexamethasone
What this could lead to: If successful, this study could reveal new ways that alpha cells influence insulin secretion, potentially pointing toward better treatments for diabetes.
What could go wrong: This is a very early, small study (30 people) focused on understanding basic biology, not testing a treatment. It may not lead to any direct medical benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES (DM)

Contacts and locations

Locations

Duke Center for Living
RECRUITING

Durham, North Carolina, 27705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.